TransEnterix

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.

TransEnterix (TRXC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

TransEnterix (TRXC) Catches Eye: Stock Jumps 6.3%

Investors need to pay close attention to TransEnterix (TRXC) stock based on the movements in the options market lately.

Implied Volatility Surging for TransEnterix (TRXC) Stock Options

TransEnterix, Inc. (TRXC) CEO Anthony Fernando on Q1 2020 Results - Earnings Call Transcript

TransEnterix (TRXC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TransEnterix (TRXC) Upgraded to Buy: Here's Why

AeroVironment

Cadence Design Systems

NVIDIA

From aiding doctors and nurses in the hospital to helping police patrol amid lockdown, robots are playing a pivotal role.

5 Mobile Robotics Stocks to Combat Coronavirus Crisis

TransEnterix, Inc.'s (TRXC) CEO Anthony Fernando on Q4 2019 Results - Earnings Call Transcript

TransEnterix, Inc. (AMEX: TRXC) unveils its next round of earnings this Monday, March 16.

TransEnterix, Inc. Common Stock Earnings Preview

TransEnterix, Inc.'s (TRXC) CEO Anthony Fernando on Q3 2019 Results - Earnings Call Transcript

TransEnterix (TRXC) delivered earnings and revenue surprises of -28.57% and -56.72%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

TransEnterix (TRXC) Reports Q3 Loss, Misses Revenue Estimates

TransEnterix (TRXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: TransEnterix (TRXC) Q3 Earnings Expected to Decline

The Senhance Surgical System's launch isn't progressing nearly as well as investors had hoped.

Here's Why TransEnterix Fell Hard on Thursday

Transenterix, Inc. (TRXC) CEO Todd Pope on Q2 2019 Results - Earnings Call Transcript

TransEnterix (TRXC) delivered earnings and revenue surprises of -12.50% and -29.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

TransEnterix (TRXC) Reports Q2 Loss, Lags Revenue Estimates

BioSpecifics Technologies

Cantel Medical

Champions Oncology

RadNet

In the long-run, does consistent market timing really matter to be a successful investor?

Simple Market Timing Strategies That Work - August 05, 2019

Earnings Preview: TransEnterix (TRXC) Q2 Earnings Expected to Decline

Investors cheered the surgical robot maker's sale of assets and the added cash the divestiture will bring.

Why TransEnterix Stock Soared Today

Transenterix (NYSE: TRXC) said Wednesday it's selling AutoLap’s assets to Great Belief International Limited for $47 million.

Transenterix Spikes Higher After Equity Investment, AutoLap Asset Sale

Investors were none too pleased with the robotic surgery specialist's first-quarter earnings report.

Why TransEnterix Stock Crumbled in the First Half of 2019

Japanese approval for its robotic surgical system provides a nice spark to the medical device stock.

Why TransEnterix Stock Is Jumping Today

Options Traders Expect Huge Moves in TransEnterix (TRXC) Stock

An analyst upgrade fueled optimism for the beaten-down stock.

Why TransEnterix Stock Jumped Today

Sales of the company's Senhance robotic surgery system took a discouraging dip in the first quarter.

Why TransEnterix Is Cratering Today

TransEnterix, Inc. (TRXC) CEO Todd Pope on Q1 2019 Results - Earnings Call Transcript

TransEnterix (TRXC) delivered earnings and revenue surprises of 0.00% and -51.53%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

News for TransEnterix Stock (TRXC)